Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of HCP1904 in Healthy Male Volunteers
NCT05407220Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Jun 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of losartan and chlorthalidone in hypertension (HTN) (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Maximum Plasma Concentration of Losartan, Area Under the Curve to Last Quantifiable Concentration of Losartan and 11 more. Started Jun 2022; status: completed.
02
Drugs
losartanchlorthalidone
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05407220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05407220.